Global ADHD Medication Shortages Intensify
Global shortages of methylphenidate—sold as Ritalin and Concerta—are straining access for families. New Zealand's government has issued supply notices, forcing practitioners to find alternatives and highlighting the need for non-pharmacological coaching strategies when medication is unstable.
The global ADHD medication shortage is a complex issue with multiple contributing factors. I have gathered information on the causes, including manufacturing delays, increased demand, and regulatory quotas set by the DEA. The timeline of the shortage, which started around October 2022, and its expansion from Adderall to other stimulants like Ritalin and Vyvanse has been established. I have also found details on the impact on various stakeholders. For the user, an executive function coach in Chicago, the impact on K-12 and college students is particularly relevant. I've found information on how the shortage affects students' academic performance and behavior, and that schools with economically disadvantaged and minority students are disproportionately affected. There is also information on the role of non-pharmacological interventions, which directly relates to the user's profession. The search results provide context on the blame game between the DEA and pharmaceutical manufacturers regarding production quotas. I have specific data points on the percentage of quotas being used and the recent increases in these quotas. I can now proceed to synthesize this information into the requested Twitter thread format. I will focus on presenting new, factual information in a concise and punchy manner, avoiding repetition of the provided card content. Each paragraph will be a self-contained "tweet" providing additional context and backstory. I have enough information to fulfill the user's request without further searching.
